[News Release] VLP Therapeutics Japan initiates Phase 1 clinical trial of T-cell inducing COVID-19 vaccine: advancing the development of a universal vaccine against multiple SARS-CoV-2 variants[News Release] VLP Therapeutics Japan initiates Phase 1 clinical trial of T-cell inducing COVID-19 vaccine: advancing the development of a universal vaccine against multiple SARS-CoV-2 variants
[News Release] VLP Therapeutics Japan initiates Phase 1 clinical trial of T-cell inducing COVID-19 vaccine: advancing the development of a universal vaccine against multiple SARS-CoV-2 variants
VLP Therapeutics Japan, Inc. (VLPT Japan), a Tokyo-based biotech company, announced on March 31 the initiation of a Phase 1
[News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience][News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience]
[News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience]
VLP Therapeutics Japan, Inc. (VLPT Japan) researchers and their colleagues at the National Institutes of Biomedical Innovation, Health and Nutrition
[News Release] VLP Therapeutics awarded US$ 2.8 million grant to develop novel malaria vaccines that improve protection, reduce costs, expand equitable access[News Release] VLP Therapeutics awarded US$ 2.8 million grant to develop novel malaria vaccines that improve protection, reduce costs, expand equitable access
[News Release] VLP Therapeutics awarded US$ 2.8 million grant to develop novel malaria vaccines that improve protection, reduce costs, expand equitable access
Maryland, US-based biotech company VLP Therapeutics, Inc. (VLPT) announced today that it has been awarded a two-year grant of over
- [News Release] VLPT, Boston U, NIH researchers harness 5-methylcytidine to fine-tune immune responses in replicon mRNA vaccines, paving the way for safer next-gen immunization [Science Translational Medicine]
[News Release] VLPT, Boston U, NIH researchers harness 5-methylcytidine to fine-tune immune responses in replicon mRNA vaccines, paving the way for safer next-gen immunization [Science Translational Medicine]
[News Release] VLPT, Boston U, NIH researchers harness 5-methylcytidine to fine-tune immune responses in replicon mRNA vaccines, paving the way for safer next-gen immunization [Science Translational Medicine]
VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at Boston University and the National Institutes of Health (NIH) have demonstrated
[News Release] VLP Therapeutics Teams with Swedish AI Biotech Nygen Analytics on Vinnova-Funded Cancer Immunotherapy Research
Swedish-US partnership to develop predictive models that could transform personalized cancer treatment selection Gaithersburg, USA and LUND, Sweden, 11 November